TONMYA

TONMYA Beats Placebo on FIQR in Both Phase 3 Fibromyalgia Trials

Image
TONMYA Beats Placebo on FIQR in Both Phase 3 Fibromyalgia Trials

BERKELEY HEIGHTS, N.J. -- November 19, 2026 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) reported that TONMYA fibromyalgia treatment beat placebo on both the symptoms and function domains of the Fibromyalgia Impact Questionnaire-Revised (FIQR) at Week 14 in two Phase 3 trials. The result was significant at p≤0.001 in RESILIENT and nominally significant at p0.01 in RELIEF.

Tonix presented the analysis at the IASP 2026 World Congress on Pain in Bangkok, held October 26-30, 2026. That is about 11 months after the November 2025 commercial launch of the drug, which the FDA approved on August 15, 2025.

Tonix adds 21 million Medicare lives for TONMYA in second payer deal

Image
Tonix adds 21 million Medicare lives for TONMYA in second payer deal

BERKELEY HEIGHTS, N.J. -- November 19, 2026 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced on September 22, 2026 a second managed Medicare agreement for its fibromyalgia drug TONMYA, adding about 21 million Medicare lives. Medicare coverage for TONMYA now totals 32 million lives, or 58% of about 55 million Medicare lives in the U.S.

The agreement took effect immediately. By our calculation, it nearly triples earlier Medicare coverage: 32 million minus 21 million leaves about 11 million lives before the deal, roughly 20% of the Medicare population, against 58% now.

Total payer coverage for TONMYA reaches 53% of U.S. lives

Tonix says commercial and government coverage now totals about 166 million lives, 53% of about 314 million U.S. lives. Medicare accounts for about 19% of that total (32 million of 166 million). By our calculation, about 148 million lives, or 47%, remain outside coverage.

Tonix names Thomas Englese its first chief commercial officer

Image
Tonix names Thomas Englese its first chief commercial officer

BERKELEY HEIGHTS, N.J. -- November 19, 2026 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) promoted Thomas Englese to chief commercial officer, effective immediately, in an announcement dated Sept. 8, 2026. CEO Seth Lederman calls it the company's first CCO appointment. Englese had held the title of executive vice president, commercial operations, since September 2024, which works out to two years.

Englese keeps three marketed products across two indications

He continues to direct sales, marketing, market access and commercial operations for three products. TONMYA (cyclobenzaprine HCl sublingual tablets) is for fibromyalgia in adults. Zembrace SymTouch (sumatriptan injection) and Tosymra (sumatriptan nasal spray) are both for acute migraine in adults.

The release describes no change in scope. What changes is the title: the commercial organization for all three products now sits under a named C-suite officer.

Tonix Schedules CEO Lederman for 25-Minute Guggenheim Slot

Image
Tonix Schedules CEO Lederman for 25-Minute Guggenheim Slot

BERKELEY HEIGHTS, N.J. -- November 19, 2026 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) scheduled CEO Seth Lederman, M.D., to give a 25-minute company presentation at Guggenheim's 3rd Annual Healthcare Innovation Conference in Boston on Tuesday, November 10, 2026. The slot ran from 4:00 to 4:25 p.m. ET, and management also planned 1x1 investor meetings at the event, the company said in a November 4 announcement.

The company gave six days' notice, by our calculation, between the November 4 announcement and the conference date. It said a live webcast and a replay would be available under the News & Events tab in the Investors section of its website. Because the event date has passed, the replay is now the only route to the presentation. The announcement did not publish a slide deck or agenda.

Tonix names CEO's son George Lederman EVP to lead AI and deals

Image
Tonix names CEO's son George Lederman EVP to lead AI and deals

BERKELEY HEIGHTS -- November 19, 2026 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) appointed George Lederman, Ph.D., as Executive Vice President, Strategy and Transformation, effective October 30, 2026. He is the son of Seth Lederman, M.D., Tonix's President, CEO and Chairman. The company announced the hire on November 2, three days after the start date.

Lederman takes charge of AI, cost management and business development

George Lederman will lead AI initiatives across the organization, with the stated aim of improving operational efficiency and managing costs. He will also run business development, including evaluating partnerships and licensing deals meant to advance clinical programs and share development costs.